No Data
No Data
No Data
MediciNova Anti-inflammatory Drug Gets Issue Notification for New Patent
Seeking AlphaMay 7 06:46 ET
Express News | MediciNova Inc - New Patent Is Expected to Expire No Earlier Than September 2040
ReutersMay 7 06:00 ET
Express News | Medicinova Receives Issue Notification for New Patent Covering Extended-Release Formulations of Mn-166 (Ibudilast)
ReutersMay 7 06:00 ET
12 Health Care Stocks Moving In Friday's After-Market Session
GainersLongeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by
BenzingaApr 5 16:31 ET
Express News | Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO
Moomoo 24/7Apr 3 02:45 ET
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (Ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM).
GlobeNewswireApr 2 19:00 ET